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Objective: To examine tumor control, hearing preservation, and complication rates after
frameless fractionated stereotactic radiosurgery (SRS) in patients with vestibular schwan-
nomas (VS).
Methods: Thirty-seven patients treated with fractionated SRS from 2002 to 2011 were
retrospectively analyzed. Ninety-five percent were treated with 25 Gy in five fractions, tar-
geting a median tumor volume of 1.03 cc (range 0.14–7.60).
Results: With a median follow-up of 4.25 years (range, 15 months–9 years), no tumors
required an additional treatment resulting in 100% tumor control rate. Radiographic control
rate was 91% in 32 patients at a median follow-up of 3 years. Of the 14 patients with ser-
viceable hearing and with audiograms, the hearing preservation rate was 78% at a median
follow-up of 18 months. Twenty-six patients with serviceable hearing pretreatment, were
evaluated by a phone survey with a hearing preservation rate of 73% at a 5 year median
follow-up. There were two cases that developed both new increased trigeminal parasthe-
sias and facial spasms but there were no cases of facial weakness. Patient had 96% of
good to excellent satisfaction rate with the treatment at a median follow-up of 5 years.
Conclusion: Frameless fractionated SRS treatment of VS results in good rate of tumor
control. Hearing preservation rate and rates of cranial nerve toxicity are comparable to
what is reported in the literature. Patients choose this modality because of its non-invasive
nature and are generally very satisfied with their long term outcome.
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INTRODUCTION
Vestibular schwannomas (VS) are benign tumors arising mostly
from vestibular component of the vestibulocochlear nerve. They
constitute about 6% of intracranial neoplasms with an incidence
of ∼9–13 per million people per year (Murphy and Suh, 2011).
Clinically, VS are categorized as sporadic and unilateral, genetic
(NF2-associated) and bilateral, or malignant schwannomas. The
unilateral or sporadic tumors are by far the most common, making
up 95% of VS. VS are characterized by a slow growth pattern with
an increase in diameter of 1 mm per year that is most likely to hap-
pen during the first 3 years (Moffat et al., 2012). Hearing loss is the
most common initial presenting symptoms and is usually followed
by tinnitus, disequilibrium, trigeminal nerve dysfunction, vertigo
headache, facial nerve dysfunction, and diplopia (Stucken et al.,
2012). Symptoms usually arise from tumor progression as it grows
through the internal auditory canal through the cerebellopontine
angle and eventually leading to compression of neighboring cra-
nial nerves and the brainstem (Stucken et al., 2012). Treatment
protocols range from observation to microsurgical resection (MS)
or stereotactic radiation therapy (Arthurs et al., 2011). The choice
of treatment depends on the likelihood of maximizing local tumor
control while preserving hearing function and minimizing cra-
nial nerve toxicity. A recent meta-analysis of comparing long term
hearing preservation outcomes has demonstrated superiority of
radiation therapy treatment compared with observation (Mani-
akas and Saliba,2012). Studies comparing radiotherapy treatments
to microsurgery have reported better hearing preservation out-
comes of radiosurgery (RS) compared with microsurgery (Pollock
et al., 2006) although the debate continues given the heterogeneity
of sample and methodology used in the literature. A recent sur-
vey of neurotologist reported increase preference of treating these
tumors with stereotactic radiotherapy (SRT) over microsurgery
(German et al., 2011).
Various radiation therapy techniques using alternative
approaches to tumor targeting have been used for the treatment
of VS. These include stereotactic radiosurgery (SRS) using Gam-
maknife or Cyberknife or SRT using a linac-based accelerator.
Within these modalities varying radiation doses and fractionation
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regimens have been studied (Ishihara et al., 2004; Chang et al.,
2005; Arthurs et al., 2011; Collen et al., 2011; Hansasuta et al.,
2011; Murphy and Suh, 2011; Roos, 2012). Although studies have
shown equivalent tumor control rates, improved hearing preser-
vation rates have been demonstrated with lower SRS dose (Yang
et al., 2010; Arthurs et al., 2011). The effect of fractionation,
however, is less clear. While equivalent tumor control rates have
also been noted for single versus multi-fraction delivery sessions,
retrospective analyses examining hearing preservation rates have
reported mixed results ranging from superior (Andrews et al.,
2001) to equivalent hearing preservation rates with dose frac-
tionation (Meijer et al., 2003; Combs et al., 2010). The ability to
fractionate the treatment should allow normal tissue, such as the
cochlea and brainstem, to recover from radiation leading to bet-
ter hearing preservation rates. More recently, the Stanford group
published their large series update using Cyberknife based robotic
fractionated stereotactic radiosurgery (FSRS) with good tumor
control, hearing preservation, and non-auditory complication
rates (Hansasuta et al., 2011).
In this manuscript we present our long term institutional
experience using robotic FSRS but with an alternative previously
utilized fractionation regimen (Williams, 2002). Tumor control
rates, hearing preservation rates, quality of life, and non-auditory
complication rates are reported.
MATERIALS AND METHODS
PATIENT CHARACTERISTICS
From September 2002 to September 2011, 55 patients with VS
were treated with Cyberknife based FSRS at Georgetown Univer-
sity Hospital. All data were reviewed under an institutional review
board-approved retrospective protocol. Patients with neurofibro-
matosis type 2 were excluded from the analysis. A minimum of
12 month follow-up was required to be included in the analy-
sis. Eighteen patients had either no (n= 9) or ≥1 year (n= 9)
follow-up data. Thirty-seven patients with≥1 year follow-up data
were analyzed. Pre and post-treatment radiographic digital imag-
ing was only available on 32 patients. Nineteen patients had pre-
and post-audiogram data for analyses, 14 of which had serviceable
hearing. Hearing, facial nerve function, tumor volume/mass effect
were analyzed with the Gardner and Robertson (1988), House
and Brackmann (1985), and Koos et al. (1998) scales, respec-
tively. Twenty-nine patients were reached by phone and perception
of hearing preservation as well as overall satisfaction with the
treatment was evaluated.
Patient characteristics are summarized in Table 1. The median
age was 58 (range 31–85) with a 70% male majority. The later-
ality was divided almost equally between the left and right side.
None of the patients had received any prior treatment for their
tumor. Majority of the patients (81%) presented with hearing loss
as an initial symptom while ataxia/disequilibrium and tinnitus
were presenting symptoms in 57 and 46% of the patients, respec-
tively. None of the patients had any symptoms of facial nerve
involvement on presentation.
TREATMENT CHARACTERISTICS
Treatment characteristics are presented in Table 2. The median
tumor volume was 1.03 cc with a range from 0.14 to 7.60 cc. The
vast majority of the patients (95%) were treated with 25 Gy in
Table 1 | Patient characteristics.
Age (median, range, years) 58 (31–85)
GENDER n (%)
Male 26 (70)
Female 11 (30)
LOCATION n (%)
Right 18 (49)
Left 19 (51)
PRIOR SURGERY n (%)
Symptoms at presentation 0 (0)
Trigeminal paresthesias 1 (2.7)
Trigeminal neuralgia 0 (0)
House–Brackmann facial nerve function Grade 1 37 (100)
Hemifacial spasms 0 (0)
Hearing loss 30 (81)
Tinnitus 16 (46)
Ataxia/disequilibrium 20 (57)
Table 2 |Treatment characteristics.
Tumor volume, median (range), cc 1.03 (0.14–7.60)
KOOS CLASSIFICATION n (%)
I 13 (35)
II 20 (54)
III 4 (11)
IV 0 (0)
SESSION, n/TOTAL DOSE, Gy n (%)
5/25 35 (95)
3/21 2 (5)
five sessions while only two patients were treated to 21 Gy in three
fractions. The majority of the tumors (54%) were Koos Grade 2.
The conformity index (prescribed isodose volume/tumor volume
encompassed by the prescription isodose line) and the modified
conformity index [(prescribed isodose volume × tumor volume
encompassed by the prescription isodose line)/tumor volume] was
calculated on all patients (Collins et al., 2006). The median confor-
mality index was 1.60 with a range of 1.01–2.59 while the median
prescription isodose line was 80% with a range from 60 to 92%.
RADIOSURGICAL TECHNIQUE AND FOLLOW-UP
The CyberKnife FSRS system (Accuray, Inc., Sunnyvale, CA, USA)
uses a 6-MV X-band linear accelerator (LA) mounted on a fully
articulated robotic arm. During treatment, two orthogonally posi-
tioned x-ray detectors provide real-time imaging of bony anatomy
allowing for intrafraction movement correction. Treatment was
generally administered on an outpatient basis with each treatment
lasting∼45–90 min. Most of the patients received their treatments
over the course of five consecutive days.
Patients were immobilized in the supine position with an
Aquaplast facemask (WRF/Aquaplast Corp., Wyckoff, NJ, USA).
All patients underwent a treatment planning computed tomog-
raphy (CT) scan (1.25 mm slices) fused with high resolution
Fast Imaging Employing Steady State Acquisition (FIESTA) mag-
netic resonance imaging (MRI) scans. The radiation oncologist,
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neurosurgeon, or neurotologist, and radiation physicist performed
tumor delineation, dose selection, and planning. Inverse plan-
ning was used to determine the dose to the target volume while
minimizing the dose to normal tissue, especially the cochlea and
vestibular organ. Target coverage, coformality index, and dose het-
erogeneity were examined to evaluate the quality of treatment
plans. Informed consent was obtained from all patients.
Patients typically underwent a post-treatment surveillance with
an MRI scan, audiogram, and clinic visits 6 months after the com-
pletion of FSRS for the first 2 years then annually thereafter. Five
years after treatment, follow-up visits were conducted every other
year. A follow-up phone interview was conducted for the pur-
poses of this study. Patients were asked the reason for choosing
this type of treatment, their recollection of presenting sympto-
matology, improvement of symptoms, and development of any
new symptoms since the treatment. Patients were also asked if
their hearing has changed since the treatment and if worsening
is noted, whether that has impacted their daily function. Inquiry
about any additional treatments and their overall satisfaction with
the treatment was also addressed in the phone survey. An attempt
was made to call all 37 patients by phone. Twenty-eight patients
were surveyed, but only 26 participated in the hearing preservation
portion of the survey.
STATISTICAL ANALYSIS
Tumor control rate was assessed using two definitions. Interven-
tional tumor control rate was defined as the absence of the need
for additional surgical or radiosurgical intervention according to
the Stanford update series (Hansasuta et al., 2011). Radiographic
tumor control was defined as progression on the follow-up MRI
according to a neuroradiologist interpretation. Kaplan–Meier
product-limit method was used to calculate tumor control rate
and patients were censored at the time of their last follow-up.
Hearing preservation was defined as maintenance of Gardner–
Robertson Grade 1– 2 hearing after SRS. Given that the number
of events was very small for tumor control correlational analyses
was not conducted. For the phone survey, hearing preservation as
a perception of same or worse compared to pretreatment baseline.
Satisfaction with overall treatment was grouped into four cate-
gories: dissatisfied, fine, or good, very good, and excellent. Analyses
were performed in SAS version 9.2 (SAS Institute Inc., Cary, NC,
USA).
RESULTS
TUMOR CONTROL
The interventional tumor control rate was 100% at a median
follow-up of 4.25 years, as none of the tumors displayed enough
growth to require additional treatment. The radiographic control
rate was 91% at a median follow-up of 3 years and an actuar-
ial follow-up of 5 years (Figure 1; Table 3). The median time to
progression was 20 months. Patients who had radiographic pro-
gression were Koos Grade 2 or higher, but statistical correlation
could not be established due to small number of events.
HEARING PRESERVATION
Of the 37 patients, 19 patients had both pretreatment and follow-
up audiograms. Five (26%) patients had non-serviceable hearing
(GR Grade 3, 4, or 5) before SRS. With a median follow-up
of 18 months, 11 of 14 patients maintained serviceable hearing
resulting in a crude hearing preservation rate of 78% (Table 3).
Further examination revealed that for Koos Grade 1, hearing
FIGURE 1 | Kaplan–Meier curve showing radiographic tumor control in 32 patients treated with radiosurgery for vestibular schwannoma between
2002 and 2011.
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Table 3 |Treatment outcomes.
Interventional tumor control rate % (n,
median follow-up)
100% (37, 4.25 years)
Radiographic tumor control rate % (n,
median follow-up)
91% (32, 3 years)
Crude hearing preservation rate % (n,
median follow-up)*
78% (14, 18 months)
Koos I 100%
Koos II, III 71.6%
OTHER COMPLICATIONS
Increased trigeminal parasthesias 2 (5)
New facial paresis 0 (0)
Hemifacial spasm 2 (5)
Hydrocephalus 0 (0)
New tinnitus 3 (8)
New ataxia/disequilibrium 1 (2)
*For those with serviceable hearing (GR scale 1–2).
preservation was 100% while those with Koos Grade 2 and above
had a 72% hearing preservation rate. Personal impression of
hearing preservation was also assessed by phone on 26 patients.
With median follow-up of 5 years, the crude hearing preserva-
tion rate was 73% (19 patients reporting same hearing and 6
reporting worsening hearing loss). Twelve patients had missing
audiograms (pretreatment, post-treatment, or both). Out of these
12, 10 patients reported no change in hearing while two reported
worsening hearing. There were 10 patients with documented ser-
viceable hearing pretreatment (Table 3). Four patients reported
worsening hearing despite the fact that the audiogram documen-
tation showed only two patients progressing to the non-serviceable
category. Among those with non-serviceable pretreatment audio-
grams (GR 3–5), three out of four patients reported same hearing
whereas one reported worsening hearing (Table 4). When asked
how the change in hearing has impacted daily function, 21 patients
indicated no impact (81%) while 5 patients indicated worsening
daily functioning as a result of their hearing impairment (19%).
NON-AUDITORY COMPLICATIONS AND OVERALL SATISFACTION
Non-auditory complications are summarized in Table 3. There
were two trigeminal nerve complications (5%). Both patients
developed trigeminal parasthesias and hemifacial spasms, the lat-
ter required treatment with pharmacological agents with resolu-
tion of symptoms. There were no reports of trigeminal neuralgia
or facial weakness. There were no cases of hydrocephalus. Three
patients reported new onset tinnitus, while one with pretreatment
tinnitus reported resolution of symptoms. Additionally, seven
patients who presented with ataxia/disequilibrium reported res-
olution of symptom. One patient, however, reported new onset
disequilibrium resulting in impairment of her daily functioning.
When asked why they chose this treatment, the vast majority
of the respondents cited the non-invasive nature of the proce-
dure and fear of nerve damage during surgery 24/26. Two patients
were also inoperable and two cited hearing preservation as the
main reason for choosing SRS. The majority of those surveyed
were satisfied with the treatment. Thirteen patients responded Ta
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good or fine (46%), 2 patients responded very good (7%), and 12
patients responded excellent, outstanding, or great (43%). Only
one patient who had developed facial spasms was dissatisfied with
the treatment (4%).
DISCUSSION
In this paper we presented our institutional experience with
frameless robotic Cyberknife based FSRS. Our results show good
tumor control with 100% interventional tumor control rate and
91% radiographic tumor control rate at a median follow-up of
4.25 years. Multiple studies report similar high rates of tumor
control with various radiation treatment modalities including
Gamma Knife based SRS, LA-based SRS, conventionally fraction-
ated stereotactic radiation therapy, proton beam radiation therapy
[reviewed in (Arthurs et al., 2011; Murphy and Suh, 2011)]. Results
from publications with the frameless Cyberknife based FSRS using
the Cyberknife system have also been similar. Ishihara et al., 2004,
reported a 94% radiographic tumor control rate at a median
follow-up of 27 months using the same system (Ishihara et al.,
2004) while the Stanford series reported a radiographic control
rate of 98% at a mean follow-up of 48 months (Chang et al.,
2005). In their recent update, the Stanford group reported an
interventional tumor control rate of 99 and 96% at 3 and 5 years,
respectively with the use of multisession SRS results (Hansasuta
et al., 2011). While the latter study represents the largest and most
comprehensive experience with this system, a direct comparison
of our results and the above studies remains difficult as the adher-
ence to the 2003 Consensus Reporting Standards (Kanzaki et al.,
2003) is highly variable between the studies. A recent meta-analysis
attempting to examine outcome differences between observation
and stereotactic radiation therapy for the management of VS,
could not include fractionated SRT as none met the criteria of
the meta-analysis (Maniakas and Saliba, 2012).
Our hearing preservation rates are also comparable to what
has been published with SRS (Delbrouck et al., 2011; Murphy
and Suh, 2011; Roos, 2012) and with frameless Cyberknife FSRS
(Ishihara et al., 2004; Chang et al., 2005; Hansasuta et al., 2011).
Here we report a hearing preservation rate of 78% at median
follow-up of 18 months and 73% based on patient’s report at
a median follow-up of 5 years. Not surprisingly we found that
tumor control rate for the smaller sized tumors (Koos I) was
100% and is lower for larger tumors. This is similar to the results
by Hansasuta et al. (2011), who reported a hearing preservation
rate of 85 and 75% at a median follow-up of 3 years for Koos
I, and Koos Grade 2 or higher, respectively. Although previous
studies with the Cyberknife FSRS system also used a fractionated
regimen, the majority of our patients received a different frac-
tionation scheme of 5 Gy delivered in five fractions. The value
of fractionated SRS is that it allows for delivery of highly con-
formal treatment of targets that are in close proximity to critical
structures such as the cranial nerves. We hypothesized that fur-
ther fractionation would improve the therapeutic ratio, thereby
reducing the risk of late complications potentially associated with
a large single dose or fewer and larger fractions. Indeed, a recent
dosimetric comparison of LA-based (BrainLAB) and robotic RS
(CyberKnife) systems for VS showed while there is no significant
differences in conformity index between the two systems, organs
at risk including the choclea and the mesial bone received sig-
nificantly lower doses with the robotic Cyberknife system (Dutta
et al., 2012). This analysis, however, was a dosimetric one and
not based on clinical outcomes. Our results show a 5% facial
and trigeminal nerve toxicity at a median follow-up of 4.25 years.
Rates of new onset permanent and transient facial weakness of 0–5
and 1–10%, respectively, have been reported after single fraction
SRS (Delbrouck et al., 2011; Murphy and Suh, 2011). In the Stan-
ford update, Hansasuta et al. (2011) reported at 3.6 year median
follow-up a 0.5 and 1.6% trigeminal and facial nerve toxicity rates,
respectively, using a fractionation of scheme of 6 Gy delivered
in three fractions (Hansasuta et al., 2011). Given the retrospec-
tive nature of these studies a conclusion about the superiority of
one fractionation regimen over the other cannot be made due to
the inherent biases associated with the study design but calls for
the need for prospective trials comparing the two fractionation
regimens.
Our phone survey demonstrated good to excellent satisfaction
rate of 96% at a median follow-up of 5 years. This suggests that
the nature and degree of the side effects do not interfere with their
quality of life. However, a direct quality of life assessment was not
conducted in this study and this question would require further
assessment. The discordance between hearing preservation results
by self report and by audiogram analysis also highlights this point.
Whether this discrepancy is due to the longer median follow time
with the self report data than that of audiogram, or whether it is
due to a perception of a decline in quality of life remains to be
determined. A systemic review of quality of life management of
VS comparing MS with radiation treatments showed that although
the efficacy of the two seemed equivalent, such significant hetero-
geneity among the trials existed to a degree that a meta-analysis
could not be performed (Gauden et al., 2011). A VS specific quality
of life assessment scale developed at the University of Pennsylva-
nia (PANQOL scale) has been validated and shown superiority to
the Short Form-36 (SF-36) Health Survey (Shaffer et al., 2010).
This will be a potentially a very critical outcome measure in trials
examining the correlation between clinical indicators and quality
of life outcomes in patients with VS.
CONCLUSION
This study has demonstrated the feasibility of using frameless frac-
tionated SRS with 25 Gy in five fractions with good long term
tumor control rates. Our results also show this to be an attrac-
tive modality for patients with this disease given its non-invasive
nature. Hearing preservation rate and rates of cranial nerve toxi-
city are comparable to what is reported in the literature. Patients
were very stratified with their outcome long term. Our retrospec-
tive review is, however, limited by potential selection bias, sample
size, and heterogeneous patient population. Additionally, the fact
that the majority of the tumors in our study were of Koos classifi-
cation I and II, a group with historically excellent outcomes, biases
our results and raises questions about whether an actual benefit
for hypofractionation exists for these classifications. Further well-
designed, multi-institutional randomized prospective research is
necessary to understand this condition, evaluate SRS treatment
modalities and fractionation regimens, as well as treatment effect
on quality of life.
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